Ventana and TriPath form global alliance:
This article was originally published in Clinica
Ventana Medical Systems and TriPath Imaging have entered a five-year supply partnership for TriPath's interactive histology imaging system. Under the terms of the agreement, Ventana obtained exclusive worldwide rights to sell and distribute the product under its own brand and to optimise it for assays developed by both Tucson, Arizona-based Ventana and Burlington, North Carolina-based TriPath. The system offers on-demand digital imaging, direct visualisation of immunohistochemistry stained slides and real time quantitative analysis of tissue samples.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.